Innovative anti-cancer therapy using red blood cells to extensively stimulate the immune system enters the clinic

On January 13, 2022, Rubius Therapeutics announced that it has completed the first patient dosing in a Phase 1/2 clinical trial of its red blood cell therapy RTX-224, designed to broadly stimulate the immune system, for the treatment of certain relapsed/refractory Patients with sexually advanced or locally advanced solid tumors, including non-small cell lung cancer, cutaneous melanoma, head and neck squamous cell carcinoma, urothelial (bladder) cancer, and triple-negative breast cancer

Rubius aims to bioengineer red blood cells to create an entirely new class of cellular drugs for the treatment of cancer and autoimmune diseases

Image source: Rubius official website

This open-label, multicenter, multidose, dose-escalation and expansion Phase 1/2 clinical trial is designed to determine the safety, resistance to RTX-224 in certain adult patients with relapsed/refractory or locally advanced solid tumors Tolerance, pharmacokinetics, maximum tolerated dose, and recommended Phase 2 dose and dosing schedule

References:

[1] Rubius Therapeutics Announces Dosing of First Patient in Phase 1/2 Trial of RTX-224, a Broad Immune Agonist, for the Treatment of Certain Solid Tumors.

(Original abridged)